ASH 2018 | Antibodies for AML: updates from ASH

Marina Konopleva

Marina Konopleva, MD, PhD, of the University of Texas MD Anderson Cancer Center, Houston, TX, discusses the key news for antibody therapies for acute myeloid leukemia (AML) from the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA. These include CD123 as a therapeutic target, novel bispecifics, and promising antibody-drug conjugates.

Share this video